Fallopian Tube Cancer
Fallopian Tube Cancer is a rare type of cancer that occurs in the fallopian tubes, which connect the ovaries to the uterus. Symptoms may include abdominal pain, unusual vaginal bleeding, and pelvic discomfort.
Ovarian Cancer: REGN5668 with Cemiplimab or REGN4018
We are studying the safety and effectiveness of REGN5668 when given with either Cemiplimab or REGN4018 for patients with ovarian cancer. This trial aims to find the best dose and see how well these combinations work.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Primary Peritoneal Cancer
Primary Peritoneal Cancer is a rare cancer that starts in the peritoneum, the lining of the abdominal cavity. It often presents with symptoms similar to ovarian cancer, such as abdominal swelling and discomfort.
Ovarian Cancer
Ovarian Cancer is a type of cancer that begins in the ovaries. It can cause symptoms like abdominal bloating, pelvic pain, and changes in urinary habits, often going undetected until advanced stages.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 18 and 75 years old?
- Do you have advanced ovarian cancer, primary peritoneal cancer, or fallopian tube cancer?
- Have you received at least one treatment with platinum-based chemotherapy?
- Do you have a life expectancy of at least 3 months?
- Are you currently taking any corticosteroids like Prednisone or Dexamethasone?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Regn4018
Regn5668
Ubamatamab
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
UZ Leuven
Gynecologic Oncology
Heverlee, Belgium
Institut Bergonie
Medical Oncology Department
Bordeaux, France
Centre Francois Baclesse
Medical Oncology-Cancerology Department
Caen, France
Sponsor: Regeneron Pharmaceuticals Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.